advanced search
Pascale Farjas
Global Category Manager, ENT Products
Nemera

Is this your profile?

About

Pascale Farjas is the Global Category Manager for Nemera’s ENT segment. She joined Nemera in 2011 and holds a degree in Chemical Engineering from the National Institute of Applied Sciences (Rouen, France), with an MBA from the Institut d’Administration des Entreprises (Lyon, France). With her technical acumen and over 15 years’ experience in marketing, her role encompasses understanding patients’ needs and regulatory requirements to develop and market packaging solutions that improve the user experience. She is in charge of the market introduction of new product platforms for nasal sprays.

Contributions

RESPIRATORY
INTEGRATED TURNKEY SOLUTIONS: KEY TO SUCCESSFUL NASAL COMBINATION PRODUCT DEVELOPMENT
Alain Regard, Audrey Chandra and Pascale Farjas discuss the use of the nasal route for locally and systemic-acting drug treatments.

More contributions

NASAL
PATIENT SAFETY: KEY DRIVER TO PRESERVATIVE-FREE NASAL SPRAY DEVELOPMENT
Benoît Guillard, Pascale Farjas  and Audrey Chandra look at the effects of preservatives in nasal sprays, and the challenges and advantages of delivering preservative-free nasal spray drugs.
NASAL
INFLUENCE OF THE HUMAN FACTOR ON NASAL DRUG DELIVERY DEVICE EVALUATION
Pascale Farjas, Alain Regard and Guillaume Grevin, discuss what is required of a modern nasal spray pump and how introducing the human factor showed a significant impact on the variability of delivered volume.
NASAL
THE DEVELOPMENT PATH TO BIOEQUIVALENCE FOR A NASAL SPRAY
Pascale Farjas, Alain Regard, and Céline Petitcolas discuss the steps taken when designing a nasal spray device for the growing bioequivalence market and the key competencies, including experience with regulations and regulatory agencies in numerous geographic regions, that Nemera can offer throughout the process.
NASAL
A TRUE PLATFORM OFFERING EFFICIENT NASAL DOSE DELIVERY
Millions of people suffering from allergic rhinitis use nasal sprays manufactured by Nemera every day. Pascale Farjas, provides an overview of an innovative nasal delivery system, Advancia®, a true platform.
NASAL
BIOEQUIVALENCE FOR NASAL SPRAYS: IMPORTANCE OF DEVICE PERFORMANCE
Pascale Farjas describes the company’s Device Equivalence Program, which enables Nemera to preselect and propose an appropriate delivery system per identified drug to companies wishing to save time in their nasal spray development pipeline.
Top